NENatonalinsutute forHealth and Care ExcellenceNICE贝guidancePembrolizumab pluschemotherapy with orwithout bevacizumab forpersistent,recurrent ormetastatic cervical cancerTechnology appraisal guidancePublished:3 May 2023www.nice.org.uk/quidance/ta885NICE 2023.All rights reserved.Subject to Notice of rights (https://www.nice.org.uk/temms-and-conditions#notice-of-rights).